2. Bibliografía

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.Clin Cancer Res. 1999; 5(10):2798-2805.

Brattström D, Bergqvist M, Lamberg K, Kraaz W, Scheibenflug L, Gustafsson G, Inganäs M, Wagenius G, Brodin O. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol.1998;15(4):255-61

resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol. 2003; 170 (4 Pt 1):1383-1387.

Goff BA, Paley PJ, Greer BE, Gown AM Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.Gynecol Oncol. 2001; 81(1):18-24.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura MPredictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003; 94(4):394-399.

Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst. 1995; 87(16):1230-1237.

Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ.Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol. 1996; 148(3):877-887.

Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 1997; 3(7):1195-1200.

Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 1998 Apr 10; 273(15):8971-4.

Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer. 1997; 71(5):787-795.

Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP, Scheper RJ. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol. 1999; 52(6):450-454.

Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene. 2003; 22(47):7458-7467.

Pohl G, Filipits M, Suchomel RW, Stranzl T, Depisch D, Pirker R.Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res. 1999; 19(6B):5051-5055.

Pohl G, Suchomel RW, Stranzl T, Depisch D, Stiglbauer W, Filipits M, Pirker R. Expression of the lung resistance protein in primary colorectal carcinomas. Anticancer Res. 2001; 21 (1A):201-204.

Volm M, Mattern J, Koomägi R. Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anticancer Drugs. 1997;8(10):931-6.

Berger W, Elbling L,Micksche M Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer. 2000; 88(2):293-300.

Dingemans AM, van Ark-Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, Giaccone G. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol. 1996 Aug;7(6):625-30.

Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, Germa-Lluch JR, Izquierdo MA. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung

Ramani P, Dewchand H. Expression of mdr1/P-glycoprotein and p110 in neuroblastoma. J Pathol. 1995 Jan;175(1):13-22.

Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M,Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995; 55(21):5038-5042.

Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol. 1995 Dec;147(6):1545-52.

Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein Nat Med. 1995;1(6):578-582.

Schroeijers AB, Siva AC, Scheffer GL, de Jong MC, Bolick SC, Dukers DF, Slootstra JW, Meloen RH, Wiemer E, Kickhoefer VA, Rome LH, Scheper RJ. The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines.Cancer Res. 2000; 60(4):1104-1110.

Schroeijers AB, Reurs AW, Scheffer GL, Stam AG, de Jong MC, Rustemeyer T, Wiemer EA, de Gruijl TD, Scheper RJ. Up-regulation of drug resistance-related vaults during dendritic cell development J Immunol. 2002; 168(4):1572-1578.

Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R, Akiyama S. Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep. 2006; 15(3):645-652.

Silva P, West CM, Slevin N, Valentine H, Ryder WD, Hampson L, Bibi R, Sloan P, Thakker N, Homer J, Hampson I. Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinomaInt J Radiat Oncol Biol Phys. 2007.

Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, Kickhoefer VA, Rome LH.Up-regulation of vaults may be necessary but not sufficient for multidrug resistance.Int J Cancer. 2001; 92(2):195-202.

Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. Cellular functions of vaults and their involvement in multidrug resistance.Curr Drug Targets. 2006; 7(8):923-934.

Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma.Relationship with poor prognosis. Cancer 1997; 79 (12):2336-2344.

Van der Pol JP, Blom DJ, Flens MJ, Luyten GP, de Waard-Siebinga I, Koornneef L, Scheper RJ, Jager MJ. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines. Invest Ophthalmol Vis Sci. 1997 Nov; 38(12):2523-30.

Volm M, Rittgen W. Cellular predictive factors for the drug response of lung cancer. Anticancer Res. 2000; 20 (5B):3449-3458.